Anti–tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection
Article first published online: 11 OCT 2004
Copyright © 2004 by the American College of Rheumatology
Arthritis Care & Research
Volume 51, Issue 5, pages 800–804, 15 October 2004
How to Cite
Parke, F. A. and Reveille, J. D. (2004), Anti–tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis & Rheumatism, 51: 800–804. doi: 10.1002/art.20702
- Issue published online: 11 OCT 2004
- Article first published online: 11 OCT 2004
- Manuscript Accepted: 8 MAR 2004
- Manuscript Received: 31 OCT 2003
- Rheumatoid arthritis;
- Tumor Necrosis Factor blockers;
- Hepatitis C
To examine the safety of using anti–tumor necrosis factor (TNF) therapy in patients with rheumatoid arthritis (RA) in the setting of hepatitis C virus (HCV) infection.
The charts of 5 patients known to have RA requiring anti-TNF therapy as well as established HCV infection were reviewed retrospectively for laboratory data of hepatic parenchymal inflammation and viral proliferation while taking these agents.
In a mean ± SD followup period of 41 months (± 28.2 months), no patient displayed evidence of sustained elevation of serum aminotransferases during therapy with anti-TNF. Additionally, 1 patient was observed to have a decreased HCV viral load after extended treatment with only anti-TNF (no therapy for HCV).
Anti-TNF therapy for RA in the setting of HCV appears to be safe and well tolerated without apparent influence on the underlying HCV infection. Therefore, this approach should be further evaluated prospectively for longterm safety.